Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04584112 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT04584112 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 83 participants.
The verdict
NCT04584112, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).
Interventions
- DRUG Atezolizumab
- DRUG Nab-paclitaxel
- DRUG Tiragolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2023-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04584112
The ClinicalTrials.gov registry entry for NCT04584112 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT04584112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04584112 about?
NCT04584112 is a clinical study titled "A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer". The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).
What is the current status of trial NCT04584112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2020-09-28. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT04584112?
The interventions under investigation include: Atezolizumab (DRUG), Nab-paclitaxel (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT04584112?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.